Skip to main content
. 2020 Jan 22;10(2):169. doi: 10.3390/biom10020169

Figure 6.

Figure 6

Antibacterial activity of CLE-CuONPs against MDR bacterial growth. Changes in the absorbance (OD620 nm) of clinical bacterial isolates at increasing CLE-CuONPs concentrations (AC). (A) Gram-negative ESβL producing E. coli-336; (B) Gram-positive methicillin-sensitive MSSA-2, and (C) methicillin-resistant MRSA-1; (D) shows reduction in percent cell viability of clinical isolates treated with 250, 500, 1000, 1500 and 2000 μg/mL of CLE-CuONPs.